The Cooper Companies, Inc.
Can CooperVision turn its contract wins and new lenses into market-level growth, or is the revenue shortfall a lasting execution problem?
Last 4 earnings calls · through Q3 FY2026
Bull case
Premium lens and myopia portfolio
CooperVision's premium daily lenses and myopia control products keep taking share and earn more revenue per patient than the older lenses they replace.
Fertility cycle recovery
CooperSurgical's fertility business is recovering as clinic treatment cycles improve, and capital equipment and genomics sales are winning new accounts.
Cash generation and buybacks
Strong free cash flow and a larger buyback authorization let management return capital and still fund the sales and marketing investment CooperVision needs.
Contact lens market leadership
CooperVision is the largest contact lens maker by number of wearers, and its scale and incumbency support pricing and access to retail accounts.
Bear case
CooperVision forecast reductions
The bear case is that CooperVision's shortfall is self-inflicted: management has repeatedly cut its growth forecast and now names its own sales coverage as the constraint.
Asia Pacific demand softness
Weak consumer spending in Japan and China and a shift to online purchasing are delaying the Asia Pacific recovery that management expected to be over by now.
Super premium product gap
Cooper sells no super premium daily lens, so it is absent from the part of the contact lens market that is growing fastest and paying most per patient.
No sale from strategic review
The strategic review ended without a transaction, so the two businesses stay combined and the execution problems that held back growth remain unresolved.
Bull and bear points
Growth & Execution
In short: MyDay and MiSight are growing double digits, while CooperVision has cut its growth forecast twice this year.
MyDay toric, multifocal and Energys grow double digits
Premium MyDay lenses earn more revenue per patient and are why EMEA and U.S. demand keeps growing while sales of older hydrogel lenses shrink.
Q3 FY2026 callFertility returns to mid-single-digit growth
CooperSurgical's fertility franchise is growing again as clinic treatment cycles improve and capital equipment orders resume, which also pulls through recurring consumable sales.
Q3 FY2026 callSales force expansion adds U.S. coverage
Management is hiring sales representatives to cover about 5,000 more U.S. offices, its answer to won contracts that did not turn into revenue.
Q3 FY2026 call
CooperVision forecast cut twice
A year ago management guided CooperVision to 4.5% to 5.5% organic growth; it now guides to 3.5% to 4.5%, and segment revenue fell 0.2% last quarter.
Tone shiftQ4 FY2025 → Q2 FY2026Asia Pacific weakness is market-driven
Consumer softness in Japan and China, plus a shift to online purchasing where Cooper is weaker, keeps delaying the regional recovery management once expected this year.
Q2 FY2026 callU.S. channel inventory is being reduced
Cooper is absorbing two quarters of distributor destocking; management says the Americas would have grown about 5% without it, so reported growth understates demand.
Q3 FY2026 call
Profitability & Financial Strength
In short: Free cash flow is strong and buybacks are larger, while tariffs and a rising tax rate pressure earnings.
Free cash flow at record levels
Free cash flow over the last twelve months was $678 million, 16% of revenue, and capital spending is falling as the CooperVision capacity build finishes.
Filed financialsReorganization savings hold operating costs flat
About $50 million of annual pretax savings from last year's restructuring keeps operating expenses nearly flat while Cooper funds new product launches.
Q4 FY2025 callBuyback authorization raised by $1 billion
Cooper bought back $339 million of stock last quarter and lifted its authorization to about $1.5 billion, supporting per-share earnings while revenue growth is slow.
Q3 FY2026 call
Tariffs and product mix pressure gross margin
Guidance assumes about $22 million of tariff cost and no refunds, and management expects gross margin to fall again as lower-margin products and private label take a bigger share.
Q2 FY2026 callTax rate rises as one-time benefit fades
A one-time $307 million tax benefit flattered this year's rate; the ongoing rate rises from about 15.5% to 17.5% in fiscal 2027 as U.S. tax on foreign earnings increases.
Q3 FY2026 callRecall settlement consumes fiscal 2026 cash
Cooper recorded a $271.6 million net charge to settle claims from its 2023 embryo culture media recall, and most of that cash is paid out this fiscal year.
Q2 FY2026 call
Market Position
In short: CooperVision leads the contact lens market but has no lens in the fastest-growing super premium segment.
CooperVision is the largest contact lens maker
About one in three contact lens wearers uses a CooperVision lens, and the company has gained share for 18 straight years, supporting pricing and retail shelf space.
Q2 FY2026 callMiSight is the only approved myopia control lens
MiSight is the only contact lens approved to slow myopia in children, including in Japan and China, which underpins roughly 20% growth and defends the franchise.
Q1 FY2026 call
No lens in the super premium daily segment
The fastest-growing part of the daily lens market is the super premium tier, where Cooper has no product, limiting how much share it can take from rivals.
Q3 FY2026 callA rival non-hormonal IUD has been approved
Paragard is Cooper's only non-hormonal IUD and a high-margin product; a competing device has been approved and the board cited it as a drag on CooperSurgical's valuation.
Q3 FY2026 callStrategic review ends with no transaction
In December management launched a formal review of strategic options; in September the board concluded shareholders are better served by continued ownership.
Tone shiftQ4 FY2025 → Q3 FY2026